Skip to content

Study · In vitro (cells) · 2007

1 result

Peptide and small molecules rescue the functional activity and agonist potency of dysfunctional human melanocortin-4 receptor polymorphisms.

Xiang Z, Pogozheva ID, Sorenson NB, Wilczynski AM, Holder JR, Litherland SA, Millard WJ, Mosberg HI, Haskell-Luevano C

Biochemistry23 Jun 2007Cited by 26 (Europe PMC)

PMID17590021 (opens in a new tab)DOI10.1021/bi7007382 (opens in a new tab)PepBankPUB-17590021
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    At 13 polymorphic human MC4Rs with reduced endogenous agonist potency, MTII showed nanomolar to subnanomolar agonist potency.

    In plain wordsIn lab tests, MTII still activated 13 variant forms of the human MC4R receptor at very low concentrations.

    Peptide
    Melanotan II
    Outcome
    Not applicableAgonist potency at 13 polymorphic hMC4Rs
    Study

    humann: not reported in source

    polymorphic human MC4Rs
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    These studies resulted in the NDP-MSH, MTII, AMW3-130, THIQ, and AMW3-106 ligands possessing nanomolar to subnanomolar agonist potency at the hMC4R polymorphisms examined in this study
    1 context sentence
    Summary · context
    Herein, we have studied 13 polymorphic hMC4Rs that have been identified to possess statistically significant decreased endogenous agonist potency with synthetic peptides and small molecules attempting to identify ligands that can pharmacologically rescue the hMC4R polymorphic agonist response.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.